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Background: Acinetobacter baumannii, a significant nosocomial pathogen, has evolved resistance to almost all
conventional antimicrobial drugs. Bacteriophage therapy is a potential alternative treatment for multidrug-resistant
bacterial infections. In this study, one lytic bacteriophage, ZZ1, which infects A. baumannii and has a broad host
range, was selected for characterization.
Results: Phage ZZ1 and 3 of its natural hosts, A. baumanni clinical isolates AB09V, AB0902, and AB0901, are
described in this study. The 3 strains have different sensitivities to ZZ1, but they have the same sensitivity to
antibiotics. They are resistant to almost all of the antibiotics tested, except for polymyxin. Several aspects of the life
cycle of ZZ1 were investigated using the sensitive strain AB09V under optimal growth conditions. ZZ1 is highly
infectious with a short latent period (9 min) and a large burst size (200 PFU/cell). It exhibited the most powerful
antibacterial activity at temperatures ranging from 35°C to 39°C. Moreover, when ZZ1 alone was incubated at
different pHs and different temperatures, the phage was stable over a wide pH range (4 to 9) and at extreme
temperatures (between 50°C and 60°C). ZZ1 possesses a 100-nm icosahedral head containing double-stranded DNA
with a total length of 166,682 bp and a 120-nm long contractile tail. Morphologically, it could be classified as a
member of the Myoviridae family and the Caudovirales order. Bioinformatic analysis of the phage whole genome
sequence further suggested that ZZ1 was more likely to be a new member of the Myoviridae phages. Most of the
predicted ORFs of the phage were similar to the predicted ORFs from other Acinetobacter phages.
Conclusion: The phage ZZ1 has a relatively broad lytic spectrum, high pH stability, strong heat resistance, and
efficient antibacterial potential at body temperature. These characteristics greatly increase the utility of this phage
as an antibacterial agent; thus, it should be further investigated.
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Bacteriophage therapy is one of the emerging methods
used to overcome bacterial infections [1-3]. Bacterio-
phages are viruses that infect and kill bacteria. Theoretic-
ally, phages have several advantages over antibiotics. They
are highly specific and very effectively lyse targeted patho-
genic bacteria. They are safe because they have no activity
against animal or plant cells. Phages are ubiquitous, so* Correspondence: wangzq@zzu.edu.cn; zhaogq@zzu.edu.cn
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reproduction in any medium, provided the orisolation of new phages is a relatively rapid process that
can frequently be accomplished in days or weeks. The use
of phages as therapeutic agents was initiated in 1919,
3 years after their discovery, for the treatment of bacillary
dysentery and continued until the 1940s. Over this time
period, phages were used to treat a variety of infectious
diseases [4]. However, with the advent of antibiotics, com-
mercial production of therapeutic phages ceased in most
of the Western world [5]. Currently, there is renewed
interest in phage research and the applications of bacterio-
phages as potentially powerful antibacterial agents due to
the emergence of drug-resistant pathogens and the dearthThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Jin et al. BMC Microbiology 2012, 12:156 Page 2 of 8
http://www.biomedcentral.com/1471-2180/12/156of new antibiotics. Several studies have shown that bacter-
iophages can be used successfully for therapeutic pur-
poses, both in humans and animals [6-9]. However, more
research is required before clinical use can be re-initiated.
Before using a phage for therapeutic purposes, the isola-
tion of lytic phages and characterization of the phage are
essential.
In this study, clinical isolates of Acinetobacter bauman-
nii were collected and used as indicator hosts to screen
phages from water samples. A. baumannii mostly infects
debilitated patients in intensive care units and is asso-
ciated with high mortality rates [10,11]. Since its discov-
ery, A. baumannii has become resistant to many common
antibiotics [12]. The increasing prevalence of multidrug-
and pandrug-resistant A. baumannii strains in clinics has
rendered it one of the most important nosocomial patho-
gens [12-15]. Fortunately, lytic phages specific to A. bau-
mannii might provide an alternative to antibiotics for the
prevention and treatment of infections caused by this bac-
terium. However, to the best of our knowledge, very few
detailed characterizations of A. baumannii phages have
been published [16,17]. This paper describes the isolation
and characterization of a novel virulent phage, ZZ1, that
infects A. baumannii clinical isolates.Results
Isolation of ZZ1 and its morphology
Twenty-three A. baumannii clinical isolates were screened
for phage present in a sample of fishpond water. Among
these, only the strain AB09V could serve as an indicator
for ZZ1 in the initial screening. This phage formed clear
plaques of approximately 1-2 mm in diameter on AB09V
lawns. AB09V was thus used to propagate, purify andFigure 1 Electron micrographs of ZZ1 and infected A. baumannii AB0
negatively stained. The phage ZZ1 contained a baseplate with fibers (indic
tail (indicated by the large black arrow), which allowed for its inclusion in t
head filled with DNA, and ghost particles (indicated by the small black arro
phage head had taken place within 5 min.characterize the phage. As shown in Figure 1, the phage
ZZ1 has a 100-nm icosahedral head and a 120-nm long
contractile tail. Morphologically, phage ZZ1 can be tenta-
tively classified as a member of the Myoviridae family in
the order of Caudovirales. Most of the input phages rap-
idly adsorbed to AB09V cells. Appearance of ghost parti-
cles 5 min after mixing phages with bacteria suggested
that ejection of DNA from the phage head occurred
rapidly.Host range of ZZ1 and identification of bacterial strains
Two additional natural bacterial hosts, AB0901 and
AB0902, were found when the other 22 of the 23 A. bau-
mannii clinical isolates were used to investigate the host
range of ZZ1 by spot test. This test used a higher concen-
tration of phage (108 PFU/ml) than the original screen.
Interestingly, some differences were observed in the ability
of the phage to lyse the 3 bacterial hosts (AB09V, AB0901,
and AB0902). For example, as shown Figure 2, ZZ1 was
capable of forming transparent areas on lawns of the
strains AB09V, AB0901, and AB0902. However, the mini-
mum phage concentrations required to form clear spots
on each lawn were different: AB09V required 105 PFU/ml,
AB0902 required 106 PFU/ml, and AB0901 required 108
PFU/ml. The values suggest that under the same culture
conditions, the antibacterial activity of ZZ1 was highest in
strain AB09V, followed by AB0902 and then AB0901.
There might be natural resistance mechanisms in AB0901
and AB0902; thus, the strain AB09V is likely the most
sensitive indicator of the phage titer of the 3 strains and is
the best host for phage propagation.
The 3 strains that can be infected by ZZ1 were selected
for further detailed study. They were resistant to all of the9V. A mixture of ZZ1 phages and A. baumannii AB09V cells was
ated by the white arrow) and an icosahedral head with a contractile
he Myoviridae family of the order Caudovirales. Intact phages had a
ws) had an empty head, showing that ejection of DNA from the
Figure 2 Antibacterial activity of phage ZZ1 against three A.
baumannii strains. Serial 10-fold dilutions of phage ZZ1 were
spotted onto lawns of strains AB09V, AB0901, and AB0902 in 0.7%
agar nutrient broth at 37°C. AB09V was used as the indicator for
determination of the phage titer.
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imipenem, meropenem, cefazolin, ceftazidime, cefotaxime,
cefepime, aztreonam, ampicillin, piperacillin, amoxicillin/
clavulanic acid, ampicillin/sulbactam, piperacillin/tazobac-
tam, sulfanilamide, sulfamethoxazole and trimethoprim,
ciprofloxacin, levofloxacin, and tetracycline). Partial 16 S
rRNA genes of the 3 strains were sequenced and depos-
ited in GenBank under the accession numbers [GenBank:
JF313142] (AB09V), [GenBank: JF313143] (AB0901), and
[GenBank: JF313144] (AB0902). Nucleotide blast analysis
further confirmed that the three strains were A.
baumannii.
Stability investigation
Temperature and pH stability are two important para-
meters in the storage of therapeutic phage. Thus, the
stability of ZZ1 was investigated at different pHs and
temperatures. As shown in Figure 3, no obvious effect
on ZZ1 activity was observed after 1 h of incubation at
pH levels ranging from 4 to 9. However, the phage
completely lost its infectivity at pH 10 or higher andFigure 3 ZZ1 stability test based on pH. The phage ZZ1 was
incubated at different pH values for one hour before determination
of the number of infectious phage particles.pH 3 or lower. Within 1 h of incubation at pH 4, the
phage infectivity decreased by approximately 87%, and
a titer of 6.0 × 108 PFU/ml of active phage ZZ1 was
detected at the end of the incubation. The maximum
stability of the phage was observed at a pH between
6 and 7. In addition, the results of thermal stability
tests shown in Figure 4 suggest that ZZ1 was relatively
heat stable over 1 h at temperatures between 50°C and
60°C, and no significant loss in phage activity was
observed. At 70°C, the phage titer quickly dropped, and
no viral particles were detected after 40 min. Further-
more, phage activity was completely lost at 80°C within
the first 1 min of incubation. The ZZ1 phage lysate
retained almost 100% of its infection activity when
stored at both 25°C and 4°C for several months (data
not shown).Investigation of antimicrobial activity of ZZ1 against
AB09V at different temperatures
Optimal A. baumannii growth occurs over a very broad
temperature range [10]. As shown in Figure 5, the
AB09V lawns grew well on nutrient agar plates at tem-
peratures ranging from 25°C to 42°C. However, the anti-
microbial activity of ZZ1 is clearly influenced by
temperature variations. When the plates were incubated
at different temperatures, the minimum phage concen-
trations required to form clear spots on AB09V lawns
were different: 105 PFU/ml at 35°C, 37°C, and 39°C;
106 PFU/ml at 30°C and 40°C; 108 PFU/ml at 25°C; and
109 PFU/ml at 42°C. Thus, we concluded that ZZ1 exhi-
bits the most efficient antibacterial activity against the
AB09V strain at temperatures ranging from 35°C to
39°C, which suggested that ZZ1 could exhibit powerful
antibacterial activity against AB09V at body temperature.Figure 4 ZZ1 heat stability test. Samples were taken at different
time intervals to determine the titer of the surviving infectious
phage particles.
Figure 5 Optimal temperature for antibacterial activity of ZZ1
against A. baumannii AB09V. Serial 10-fold dilutions of phage ZZ1
were spotted onto lawns of the sensitive strain AB09V in 0.7% agar
nutrient broth at different temperatures.
Figure 6 One-step growth curve of ZZ1 on A. baumannii
AB09V. Phage ZZ1 was mixed with strain AB09V at an MOI of
approximately 10 at 37°C (The initial ratio of phage concentration to
bacterial concentration is 6.6 × 108 PFU/ml: 7.0 × 107 CFU/ml). Then,
the total phage activity (including infected bacterial cells and free
phages) was determined periodically. The decline in the
concentration of total phages occurred as a result of the binding of
multiple viral particles to one susceptible bacterial cell followed by a
rapid increase, resulting in release of phages by lysis of the infected
bacterial cells. The ZZ1 latent period was approximately 9 min, and
the burst size averaged 200 PFU per infected cell.
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The growth characteristics of ZZ1 on the sensitive indica-
tor strain AB09V were characterized under optimal
growth conditions. Phage ZZ1 exhibited high infection ef-
ficiency after mixing the phages and AB09V cells. We in-
ferred that almost all of the A. baumannii AB09V were
infected prior to the burst time of the first infected cell be-
cause the number of bacteria surviving at 9 min was less
than 100 CFU/ml. Moreover, as shown in Figure 6, the
total plaque count was 6.6 × 108 PFU/ml at the beginning
of infection (0 min), and only 2.3 × 108 PFU/ml remained
after 9 min. The difference (approximately 4.3 × 108 PFU/
ml) originated from adsorption of multiple phage particles
to one susceptible bacterial cell. The decrease in the num-
ber of phages was greater than 6-fold higher than the ini-
tial number of bacterial cells (approximately 7 × 107 CFU/
ml). These results further confirmed that almost all of the
bacterial cells could be infected within the latent period
(9 min). The number of unattached phages at the end of
the latent period (or prior to the burst time of the first
infected cells) can be estimated as the difference between
the number of the total plaque count and the initial num-
ber of bacterial cells. The calculated number of un-
attached phages was 1.6 × 108 PFU/ml, which is negligible
compared to the phage number at the end of the experi-
ment (1.5 × 1010 PFU/ml). Moreover, the number of bac-
teria surviving at the end of the experiment is less than
50 CFU/ml, which can also be considered negligible when
compared to the initial number of bacterial cells
(7.0 × 107 CFU/ml). Therefore, the average burst size was
approximately 200 PFU/cell, which can be calculated as
the ratio of the final count of phage particles to the initial
count of infected bacterial cells.Genome analysis
The phage nucleic acid was susceptible to degradation
by DNase and some restriction endonucleases (e.g., Hin-
dIII, EcoRI, and EcoRV) but unaffected by RNase. Thus,
ZZ1 is a dsDNA phage (data not shown). The ZZ1 gen-
ome has a total length of 166,682 bp and a GC content
of 34.3%, which is slightly lower than that described for
the A. baumannii ATCC 17978 strain (38%, accession
number NC_009085). An initial NCBI nucleotide blast
analysis (blastn) of the complete genome sequence indi-
cated that ZZ1 shares limited similarities with other
known phage nucleotide sequences, which confirmed its
status as a novel Acinetobacter phage species. The top 4
most similar sequences found were of the Acinetobacter
phages Acj9 [GenBank: HM004124.1], Acj61 [GenBank:
GU911519.1], Ac42 [GenBank: HM032710.1], and 133
[GenBank: HM114315.1]. The max scores were 4662
(50% of coverage, 89% of max ident), 4448 (45% of
coverage, 87% of max ident), 2634 (34% of coverage,
94% of max ident), and 2210 (31% of coverage, 92% of
max ident). The four Acinetobacter phages were recently
deposited in GenBank and were previously annotated as
T4-like phages [18]. No other Acinetobacter phages were
hit by blastn. In addition, Enterobacteria phage T4
ranked tenth, and its max score was 1972 (28% of cover-
age, 83% of max ident), suggesting that the ZZ1 phage
might be a new member of the T4-like phage family.
A sequence search using the NCBI open reading frame
(ORF) finder revealed a total of 402 putative ORFs of 50
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similarity to other known phage proteins. Among them,
118 ORFs have the highest similarity to predicted ORFs
from the Acinetobacter phage Acj9; 47 ORFs are most
similar to predicted ORFs from the Acinetobacter phage
Acj61; 18 ORFs most closely resemble predicted ORFs
from the Acinetobacter phage 133; and only 13 ORFs
have the highest score with predicted ORFs from the
Acinetobacter phage Ac42. In addition, of the 402 ORFs,
105 ORFs showed homology with sequences in GenBank
with annotated function; 244 ORFs had matches with
uncharacterized entries; and the remaining 53 ORFs had
no match to sequenced genes in the database.
Discussion
Phage therapy has been the subject of several recent
reviews, and the present study reinforces the view that it
is worth exploring [1,2,19]. To the best of our know-
ledge, the characterization of lytic phages of A. bauman-
nii has rarely been studied, although Ackermann et al.
[16,20] described the classification of an A. baumannii
phage, and Soothill et al. [1,21] tested the efficacy of
phage therapy for experimental A. baumannii infections
in mice. In this study, we focused our efforts on the iso-
lation and characterization of A. baumannii phages with
potential for prophylactic/therapeutic use.
Phages are thought to be found wherever bacteria
thrive [22]. Acinetobacter spp. are ubiquitous organisms
that can be readily isolated from non-clinical sources,
such as soil, drinking and surface waters, sewage, and a
variety of different foods [10], which suggests that
phages specific to A. baumannii might also be easily iso-
lated from nature. Recently, 10 phages were obtained
from wastewater using 125 clinical isolates of A. bau-
mannii as indicator hosts [20,23]. These phages were
designated AB1 to AB9 and AB11. Examination by
transmission electron microscopy suggested that phages
AB1-7 and AB9 belonged to the Podoviridae family, and
phages AB8 and AB11 belonged to the Myoviridae fam-
ily. Two of the 10 phages, AB1 and AB2, were further
characterized at 35°C and 37°C, respectively. Based on
morphology and genomic analysis, the two phages were
classified as new members of the ϕKMV-like phages
[20,23]. In this study, the phage ZZ1, which is specific to
A. baumannii, was isolated from fishpond water, which
further confirmed that phages specific to A. baumannii
are waiting to be exploited as an abundant natural re-
source. The ability of phage ZZ1 to form clear plaques
on lawns of AB09V is indicative of lytic phage, and a
large burst size with a short latent period is further sug-
gestive of the lytic nature of phage ZZ1. Morphologic-
ally, ZZ1 exhibits features similar to the Myoviridae
family (order Caudovirales), which, broadly, are tailed
phages with icosahedral head symmetry and contractiletail structures. Genome analysis of ZZ1 showed that it is
fairly similar to four other Acinetobacter phages (Acj9,
Acj61, Ac42, and 133). In a recent review by Petrov
et al. [18], the four Acinetobacter phages were initially
assigned to the “T4-like Viruses” genus. Each of these
Acinetobacter phages has a unique set of ORFs that oc-
cupy ~35% of the genome. That is, each represents a dif-
ferent type of T4-related phage genome [18]. The
genome size of the phage ZZ1 (166,682 bp) is also close
to the genome size of T4-like phages. These genomes
vary between ~160,000 and ~250,000 bp [18]. Therefore,
the above features confirmed that the phage ZZ1 is most
likely a new member of the T4-like virus family of Acine-
tobacter phages. However, according to the 2011 Virus
Taxonomy List (current) from the International Com-
mittee for the Taxonomy of Viruses (http://www.ncbi.
nlm.nih.gov/ICTVdb/index.htm.), only the Acinetobacter
phage 133 can be searched and classified in the un-
assigned genus of the Myoviridae family, most likely be-
cause the phage is inadequately characterized. At the
very least, the current sequence database for the Myovir-
idae phages should prove to be a rich source of genetic
markers for bioprospecting and a mine of reagents for
basic research and biotechnology. Our future research
will focus on further detailed analysis of the whole ZZ1
genome to understand the genetic characteristics of this
phage.
The main aim of this study was the isolation and
characterization of a lytic bacteriophage with potential for
prophylactic/therapeutic use. Therefore, the antibacterial
activity of the phage against its different host cells was the
focus of our research. Through the preliminary in vitro
host range investigation, ZZ1 was found to have different
antibacterial activity against 3 of its natural hosts. The
antibacterial activity of ZZ1 was highest against the strain
AB09V, followed by AB0902 and then AB0901, based on
the minimum phage concentration required to form clear
spots at 37°C. The natural resistance mechanisms of
AB0901 and AB0902 against ZZ1 are worth further inves-
tigation in future studies. With respect to its life cycle in
the sensitive strain AB09V, ZZ1 proliferates efficiently,
with a short latent period (9 min), a large burst size (200
PFU/ml), and a high adsorption rate. Remarkably, only
less than 50 CFU/ml of the AB09V cells remained viable
30 min after AB09V cells were mixed with ZZ1 particles
at a multiplicity of infection (MOI) of 10 at 37 °C. More-
over, ZZ1 exhibited the most powerful antibacterial activ-
ity at temperatures ranging from 35°C to 39°C, suggesting
that the phage would be highly effective when placed in-
side the body at normal or near normal body temperature.
In addition, ZZ1 was stable over a wide pH range (4-9)
and was strongly resistant to heat. All of these features
have implications for the use of this phage as a stable
therapeutic agent for the treatment of A. baumannii
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sitive to the phage, AB09V. The differences in the antibac-
terial activity of ZZ1 against the strains tested will be the
focus of our future research both in vitro and in vivo.
Conclusions
This study provides information about a novel virulent
A. baumannii phage. Our future research will examine
the application of this characterized phage in treating
infections by A. baumannii clinical isolates both in vivo
and in vitro.
Methods
Bacterial strains and Identification
Twenty-three clinical strains of A. baumannii were used
in this study for phage isolation and phage host investiga-
tion. All of these strains were isolated from the sputum
of hospitalized patients at the Henan Province People’s
Hospital in Zhengzhou, China. After obtaining the
approval of the Life Science Ethics Committee of
Zhengzhou University and written informed consent,
sputum samples were collected for the purposes of this
study. The automated system BD Phoenix (Becton Dick-
inson Diagnostic Systems, Sparks, MD, USA) was used
on clinical samples for the identification of bacteria and
for antibiotic susceptibility tests. Only 3 of the 23 strains
could be lysed by ZZ1; these were lysed to varying
degrees. Therefore, the 3 strains were designated AB09V,
AB0901, and AB0902 in our nomenclature. The 3 strains
selected for use in this study were further confirmed as
A. baumannii using sequence information derived from
their 16 S rRNA gene. Briefly, bacterial DNA was isolated
as previously described [24]. The extracted DNA was
used as the PCR template to amplify the 16 S ribosomal
RNA coding regions. The ClustalX 2.0 program and
Oligo 4.0 primer analysis software were used for univer-
sal primer design based on homology profiles among the
16 S rRNA genes of A. baumannii strains reported in the
GenBank sequence database. The universal primers 199f
(5' CTA CGG GAG AAA GCA GGG GAT 3') and 1344r
(5' TTA CTA GCG ATT CCG ACT TCA 3') were used
to amplify partial 16 S rRNA gene sequences. To increase
the specificity of amplification and to reduce the forma-
tion of spurious byproducts, a “touchdown” PCR was
performed (the annealing temperature decreased from 65
to 55°C for 20 cycles) as described previously [24]. The
PCR amplicons were purified with a CONCERT Rapid
PCR purification kit (Invitrogen) and were then
sequenced directly with the primers.
Bacteriophage isolation and growth
Phage isolation was conducted using the method
described by Adams [25]. Several water samples (munici-
pal sewage, fishpond water, and river water) collectedfrom different places in Zhengzhou, China, were clarified
by centrifugation (12,000 × g for 15 min at 4°C). One per-
cent (v/v) of a bacterial broth culture (overnight growth)
along with an equal volume of nutrient broth at double
concentration was added to the cleared supernatant and
incubated at 37°C overnight. The next day, after centrifu-
gation (12,000 × g for 20 min at 4°C), the supernatant was
filtered with a 0.45 μm SFCA Corning syringe filter
(Corning Inc., Corning, NY) to remove the residual bac-
terial cells. An aliquot (0.2 ml) of the filtrate was mixed
with 0.1 ml of an overnight culture of an A. baumannii
strain and 2.5 ml of molten top soft nutrient agar (0.7%
agar) at 47°C then overlaid on the surface of solidified
base nutrient agar (1.5% agar) at 37°C. After incubation
overnight at 37°C, the phage plaques were picked from
the plates, and each individual plaque was re-isolated
three times to ensure the purity of the phage isolate [26].
The phage titer was determined by the double-layered
method [25].
Phage stocks were prepared on the most sensitive bac-
terial host using the soft layer plaque technique. Briefly,
10 ml of an overnight AB09V bacterial culture was con-
centrated to 1 ml by centrifugation (3,000× g for 10 min).
One hundred microliters of the concentrated culture
(1010 CFU/ml) and 0.1 ml of the phage ZZ1 (107PFU/ml)
were added to 2.5 ml of molten top soft nutrient agar
(0.4% agar) then overlaid on the surface of solidified base
nutrient agar (1.5% agar). The plates were incubated for 6-
8 h at 37°C and were used to prepare a concentrated
phage suspension (1011PFU/ml) by eluting the top agar
overlaid plates in 5 ml SM buffer. Phage stocks were
stored at 4°C after filtration through 0.45-μm filters.
Host range investigation
The host range of the phages was examined by spot tests
on 23 A. baumannii clinical strains. A 0.1 ml aliquot of
bacterial overnight broth culture (109 CFU/ml) was
mixed with melted 0.7% soft nutrient agar (47°C), and
this mixture was poured onto 1.5% solid agar to make
double layer ager plates. When the top agar hardened,
phage stock (5 μl) from a dilution series was spotted on
each plate with different bacterial strains. The plates
were incubated at 37°C. When clearing zones were
observed, the antibacterial activity of the phages against
each bacterial host was assessed based on the minimum
phage concentration required to form a completely
transparent zone.
Investigation of ZZ1 antimicrobial activity against AB09V
at different temperatures
The antibacterial activity of ZZ1 against A. baumannii
AB09V was evaluated by serial dilution spot testing at dif-
ferent temperatures. Phage stock (5 μl) from a dilution
series was spotted onto a lawn of AB09V in top agar. The
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tions at 25°C, 30°C, 35°C, 37°C, 39°C, 40°C, and 42°C. The
optimal antibacterial temperature was determined by
comparing the minimum phage concentration required to
form a completely transparent zone.
Phage adsorption and growth curve
An overnight culture of strain AB09V (1 ml) was inocu-
lated into fresh medium (100 ml) and incubated with
shaking at 37°C for approximately 1 h to yield a cell
density of approximately 7.0 × 107 CFU/ml (at an OD600
of 0.15). A 1 ml sample of a nutrient broth suspension
of the phage ZZ1 at an approximate MOI of 10 was
added to this culture. Samples were periodically with-
drawn and immediately chilled while being further
diluted to measure total phage activity (including
infected bacterial cells and free phages) by the double-
layered-agar plate technique. Bacterial viable counts
were determined before the bacteria were mixed with
the phage and were assessed periodically. Burst size was
estimated from triplicate experiments using the equation
described by Jiang et al. [27]. Each experiment was per-
formed three times, and the results are reported as the
mean of three observations ± standard deviation (SD).
Stability
Resistance to different pH values at 37°C was deter-
mined according to the methods described by Verma
et al. [28]. The pH of the nutrient broth was adjusted
with either 1 M HCl or 1 M NaOH to obtain a pH
within the range of 2–11. A total of 100 μl of bacterio-
phage suspension (4.7 × 1011 PFU/ml) was inoculated
into 10 ml of pH-adjusted medium. After incubation for
1 h at 37°C, the surviving phages were diluted and
counted immediately using the soft agar overlay method
at 37°C. Moreover, according to the methods described
by Capra et al. [29], the stability of ZZ1 at various tem-
peratures (50°C, 60°C, 70°C, and 80°C) was checked by
incubating the phage (3.2 × 1010 PFU/ml) at the indi-
cated temperature for 1 h at pH 7.0 in nutrient broth;
the surviving phages were then counted using the soft
agar overlay method at 37°C.
Morphology of phage and its host strain
AB09V cells were infected with ZZ1 during the exponen-
tial growth phase (OD600 = 0.35) at an MOI of approxi-
mately 100 and incubated at 37°C for 5 min in nutrient
broth medium. The mixture was fixed with 1% glutaralde-
hyde at 0°C for 60 min and then centrifuged (4500× g,
3 min). The phage-cell complexes from the pellets were
placed on 300-mesh copper grids coated with carbon film
and then stained with phosphotungstic acid (2%w/v, pH
7.2) for 30 s. After drying, the preparation was examined
by a transmission electron microscope.Genome sequencing and analysis
The nucleic acid of phage ZZ1 was isolated as previously
described [20]. Purified nucleic acid was used to deter-
mine susceptibility to DNase, RNase, and restriction
enzymes and was then sent to Zhejiang California Inter-
national NanoSystems Institute (Hangzhou, China) for
commercial sequencing. The whole genome sequence,
with a total length of 166,682 bp, was obtained using the
Illumina Solexa Sequencing platform (Illumina, San
Diego, USA) and the Swift analysis tool (http://swiftng.
sourceforge.net) [30]. The genome sequence was analyzed
with the NCBI BlastX bioinformatics tool (http://blast.
ncbi.nlm.nih.gov/Blast.cgi) for nucleotide analysis, and the
NCBI ORF finder (http://www.ncbi.nlm.nih.gov/projects/
gorf/) was used to identify ORFs, which were limited to
those encoding proteins of greater than or equal to 50
amino acids. Homology assignments between genes from
other phages and predicted ORFs of phage ZZ1 were
based on amino acid sequence alignment searches (BlastP,
http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Nucleotide sequence accession number
The genome sequence, with a total length of 166,682 bp,
for phage ZZ1 described in this work was submitted to
GenBank and was assigned the accession number [Gen-
Bank: HQ698922].
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